



Released at February 7, 2011

Consolidated Financial Report
for the Year Ended December 31, 2010 (Unaudited)
AnGes MG, Inc. <http://www.anges-mg.com/>

Listings: Mothers of the Tokyo Stock Exchange, Code 4563

Head Office: 4F, Saito Bio-Incubator, 7-7-15, Saito-Asagi, Ibaraki, Osaka, 567-0085, Japan

Adoption of the U.S.GAAP: None

(Figures are rounded down to the nearest million yen)

1. Business Results for Fiscal Year 2010 (From Jan. 1, 2010 to Dec. 31, 2010)

(1) Results of Operations (Percentages indicate changes from the previous term)

	Revenues		Operating loss		Ordinary loss		Net loss	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY 2010	286	(51.0)	(2,010)	—	(1,911)	—	(1,967)	—
FY 2009	585	(38.4)	(2,610)	—	(2,783)	—	(2,921)	—

	Net loss per share	Diluted net loss per share	Return on equity	Return on asset	Operating profit ratio
	Yen	Yen	%	%	%
FY 2010	(16,668.71)	—	(37.3)	(31.4)	(666.2)
FY 2009	(24,804.64)	—	(38.1)	(33.1)	(445.8)

(2) Financial Position

	Total assets	Total net assets	Shareholders' equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
Dec. 31, 2010	5,004	4,287	82.7	35,019.99
Dec. 31, 2009	7,162	6,512	89.5	54,345.29

*Shareholder's equity Dec. 31, 2010 : 4,140 million yen Dec. 31, 2009 : 6,412 million yen

(3) Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents, at end
	Million yen	Million yen	Million yen	Million yen
Dec. 31, 2010	(1,842)	952	11	2,152
Dec. 31, 2009	(2,225)	(530)	11	3,049

2. Dividend

	Dividend per share				
	1Q	2Q	3Q	4Q	Full-year
	Yen	Yen	Yen	Yen	Yen
FY 2009	—	0.00	—	0.00	0.00
FY 2010	—	0.00	—	0.00	0.00
FY 2011 (Forecast)	—	0.00	—	0.00	0.00

3. Earnings Forecast for the Fiscal Year 2011 (From Jan. 1, 2011 to Dec. 31, 2011)

	Revenues		Operating loss		Ordinary loss		Net loss		Net loss per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
2Q, 2011	—	—	—	—	—	—	—	—	—
Full-year	250 ~350	—	(2,400) ~(2,000)	—	(2,200) ~(1,800)	—	(2,200) ~(1,800)	—	(18,607.64) ~(15,224.43)

4. Others

(1) Change of reporting entities (change of condition of significant consolidated subsidiaries) : None

(2) Change of significant accounting and reporting policies for consolidated financial statements

1) Change caused by revision of accounting standard : None

2) Other changes : None

(3) Number of shares issued and outstanding (common stock)

1) Number of shares issued and outstanding (including treasury stock)

Dec. 31, 2010 : 118,231 shares

Dec. 31, 2009 : 117,991 shares

2) Number of treasury stock

Dec. 31, 2010 : - shares

Dec. 31, 2009 : - shares

(Reference) Summary of Nonconsolidated Financial Reports

1. Business Results for Fiscal Year 2010 (From Jan. 1, 2010 to Dec. 31, 2010)

(1) Results of Operations (Percentages indicate changes from the previous term)

	Revenues		Operating loss		Ordinary loss		Net loss	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY 2010	284	(34.2)	(1,882)	—	(1,825)	—	(1,863)	—
FY 2009	432	(49.6)	(2,490)	—	(2,753)	—	(2,770)	—

	Net loss per share	Diluted net loss per share
	Yen	Yen
FY 2010	(15,786.71)	—
FY 2009	(23,519.44)	—

(2) Financial Position

	Total assets	Total net assets	Shareholders' equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
Dec. 31, 2010	4,938	4,263	83.3	34,811.65
Dec. 31, 2009	7,026	6,369	89.2	53,128.85

*Shareholder's equity Dec. 31, 2010 : 4,115 million yen Dec. 31, 2009 : 6,268 million yen

*Since descriptions about future events, for instance, earnings forecast for FY 2011, are estimation, results may differ from this estimation due to changes of several economic conditions.

**This financial report has been translated from Japanese original which has been prepared in accordance with generally accepted accounting principles in Japan, for reference purposes only. Also some changes are added to this report in order to present in a form more familiar to the readers outside Japan.

R&D Projects and its current status

<Self-developed product>

Segment	Product name / Project	Target indications	Region	Development stage	Alliance partners
Medicine	Collategene (HGF Plasmid)	Peripheral Arterial Disease (PAD)	Japan	Preparing for phase III	Daiichi-Sankyo Co., Ltd. (JP) *Marketing Rights
			US / Europe		Available
		Ischemic Heart Disease (IHD)	Japan	Preparing for clinical trials	Daiichi-Sankyo Co., Ltd. (JP) *Marketing Rights
			US	Phase I	Available
	Parkinson's Disease		Pre-clinical	Available	
	NF- κ B Decoy Oligo	Atopic Dermatitis	Japan	Phase II	Shionogi & Co., LTD.(JP) *Co-Development, Marketing Rights
US / Europe			Pre-clinical		
Medical device	Drug-Eluting PTA balloon catheter	Prevention of Vascular Restenosis		Preparing for clinical trials	Medikit Co., Ltd. Hosokawa Micron Corp. (JP) *Joint Research
	Functional Peptides	Wound		Application Research	Morishita Jintan Co., Ltd. (JP) *Joint Research

<Alliance product>

Segment	Product name / Project	Target indications	Region	Development stage	Alliance partners
Medicine	Allovecetine-7	Metastatic Melanoma	US / Europe	Phase III	Vical, Inc. (US)

<Self-developed product at GenomIdia>

Segment	Product name / Project	Target indications	Region	Development stage	Alliance partners
Medicine	GEN0101	Prostate cancer	Japan	Pre-clinical	TSD Japan, Inc.

AnGes MG, Inc
Consolidated Balance Sheets
(In thousands)
(Unaudited)

	December 31, 2009	December 31, 2010
Assets		
Current assets		
Cash and deposits	3,549,098	2,152,335
Accounts receivable-trade	64,648	78,466
Short-term investment securities	1,498,278	900,235
Merchandise	33,447	60,283
Work in process	1,798	—
Raw materials and supplies	480,416	575,333
Advance payments-trade	247,132	306,244
Prepaid expenses	28,215	25,129
Advances paid	1,089	1,656
Other	31,300	43,136
Total current assets	<u>5,935,426</u>	<u>4,142,821</u>
Noncurrent assets		
Property, plant and equipment		
Buildings	58,599	55,908
Accumulated depreciation	<u>(43,276)</u>	<u>(44,098)</u>
Buildings, net	<u>15,322</u>	<u>11,809</u>
Machinery and equipment	53,091	52,624
Accumulated depreciation	<u>(51,607)</u>	<u>(51,644)</u>
Machinery and equipment, net	<u>1,483</u>	<u>979</u>
Tools, furniture and fixtures	400,778	433,030
Accumulated depreciation	<u>(356,761)</u>	<u>(373,969)</u>
Tools, furniture and fixtures, net	<u>44,016</u>	<u>59,060</u>
Total property, plant and equipment	<u>60,823</u>	<u>71,850</u>
Intangible assets		
Patent right	195,654	150,786
Other	16,561	6,465
Total intangible assets	<u>212,215</u>	<u>157,252</u>
Investments and other assets		
Investment securities	829,443	521,739
Lease and guarantee deposits	54,784	54,131
Other	69,453	56,679
Total investments and other assets	<u>953,681</u>	<u>632,551</u>
Total noncurrent assets	<u>1,226,720</u>	<u>861,653</u>
Total assets	<u><u>7,162,146</u></u>	<u><u>5,004,474</u></u>

AnGes MG, Inc
Consolidated Balance Sheets
(In thousands)
(Unaudited)

	December 31, 2009	December 31, 2010
Liabilities		
Current liabilities		
Accounts payable–trade	49,134	98,079
Accounts payable–other	42,199	75,341
Accrued expenses	11,161	20,933
Income taxes payable	23,821	25,581
Advances received	515,101	487,665
Deposits received	7,799	8,889
Total current liabilities	<u>649,218</u>	<u>716,490</u>
Total liabilities	<u>649,218</u>	<u>716,490</u>
Net assets		
Shareholders' equity		
Capital stock	9,460,618	9,466,618
Capital surplus	7,771,361	7,777,361
Retained earnings	<u>(11,158,086)</u>	<u>(13,125,304)</u>
Total shareholders' equity	<u>6,073,893</u>	<u>4,118,675</u>
Valuation and translation adjustments		
Valuation difference on available–for–sale securities	370,141	68,357
Foreign currency translation adjustment	<u>(31,780)</u>	<u>(46,583)</u>
Total valuation and translation adjustments	<u>338,361</u>	<u>21,773</u>
Subscription rights to shares	<u>100,673</u>	<u>147,535</u>
Total net assets	<u>6,512,927</u>	<u>4,287,984</u>
Total liabilities and net assets	<u><u>7,162,146</u></u>	<u><u>5,004,474</u></u>

AnGes MG, Inc
Consolidated Statements of Operations
(In thousands)
(Unaudited)

	Year ended December 31, (From Jan. 1 to Dec.31)	
	2009	2010
Business revenues		
Net sales of goods	142,085	180,986
Research and development revenues	443,610	105,929
Total business revenues	<u>585,695</u>	<u>286,915</u>
Business expenses		
Cost of sales	68,210	82,813
Research and development expenses	2,349,721	1,439,828
Selling, general and administrative expenses	778,657	774,598
Total business expenses	<u>3,196,589</u>	<u>2,297,241</u>
Operating loss	<u>(2,610,893)</u>	<u>(2,010,325)</u>
Non-operating income		
Interest income	14,959	8,228
Foreign exchange gains	—	22,749
Subsidy income	147,367	142,306
Fiduciary obligation fee	6,031	3,317
Miscellaneous income	2,097	3,083
Total non-operating income	<u>170,456</u>	<u>179,685</u>
Non-operating expenses		
Interest paid	—	31
Stock issuance cost	272	70
Foreign exchange losses	12,448	—
Miscellaneous loss	274	—
Loss on investments in partnership	330,084	80,757
Total non-operating expenses	<u>343,080</u>	<u>80,859</u>
Ordinary loss	<u>(2,783,518)</u>	<u>(1,911,498)</u>
Extraordinary loss		
Loss on retirement of noncurrent assets	26,654	17,678
Loss on valuation of investment securities	100,029	17,879
Total extraordinary losses	<u>126,684</u>	<u>35,558</u>
Loss before income taxes	<u>(2,910,202)</u>	<u>(1,947,057)</u>
Income taxes—current	11,188	20,160
Net loss	<u>(2,921,390)</u>	<u>(1,967,217)</u>

AnGes MG, Inc
Consolidated Statements of Changes in Net Assets
(In thousands)
(Unaudited)

	Year ended December 31, (From Jan. 1 to Dec.31)	
	2009	2010
Shareholders' equity		
Capital stock		
Balance at the end of previous period	9,454,618	9,460,618
Changes of items during the period		
Issuance of new shares—exercise of subscription rights to shares	6,000	6,000
Total changes of items during the period	<u>6,000</u>	<u>6,000</u>
Balance at the end of current period	<u>9,460,618</u>	<u>9,466,618</u>
Capital surplus		
Balance at the end of previous period	7,765,361	7,771,361
Changes of items during the period		
Issuance of new shares—exercise of subscription rights to shares	6,000	6,000
Total changes of items during the period	<u>6,000</u>	<u>6,000</u>
Balance at the end of current period	<u>7,771,361</u>	<u>7,777,361</u>
Retained earnings		
Balance at the end of previous period	(8,236,695)	(11,158,086)
Changes of items during the period		
Net loss	(2,921,390)	(1,967,217)
Total changes of items during the period	<u>(2,921,390)</u>	<u>(1,967,217)</u>
Balance at the end of current period	<u>(11,158,086)</u>	<u>(13,125,304)</u>
Total shareholders' equity		
Balance at the end of previous period	8,983,284	6,073,893
Changes of items during the period		
Issuance of new shares—exercise of subscription rights to shares	12,000	12,000
Net loss	(2,921,390)	(1,967,217)
Total changes of items during the period	<u>(2,909,390)</u>	<u>(1,955,217)</u>
Balance at the end of current period	<u>6,073,893</u>	<u>4,118,675</u>
Valuation and translation adjustments		
Valuation difference on available-for-sale securities		
Balance at the end of previous period	(46,016)	370,141
Changes of items during the period		
Net changes of items other than shareholders' equity	416,158	(301,784)
Total changes of items during the period	<u>416,158</u>	<u>(301,784)</u>
Balance at the end of current period	<u>370,141</u>	<u>68,357</u>
Foreign currency translation adjustment		
Balance at the end of previous period	(33,899)	(31,780)
Changes of items during the period		
Net changes of items other than shareholders' equity	2,119	(14,803)
Total changes of items during the period	<u>2,119</u>	<u>(14,803)</u>
Balance at the end of current period	<u>(31,780)</u>	<u>(46,583)</u>

AnGes MG, Inc
Consolidated Statements of Changes in Net Assets
(In thousands)
(Unaudited)

	Year ended December 31, (From Jan. 1 to Dec.31)	
	2009	2010
Total valuation and translation adjustments		
Balance at the end of previous period	(79,916)	338,361
Changes of items during the period		
Net changes of items other than shareholders' equity	418,277	(316,587)
Total changes of items during the period	418,277	(316,587)
Balance at the end of current period	338,361	21,773
Subscription rights to shares		
Balance at the end of previous period	60,418	100,673
Changes of items during the period		
Net changes of items other than shareholders' equity	40,255	46,862
Total changes of items during the period	40,255	46,862
Balance at the end of current period	100,673	147,535
Total net assets		
Balance at the end of previous period	8,963,785	6,512,927
Changes of items during the period		
Issuance of new shares—exercise of subscription rights to shares	12,000	12,000
Net loss	(2,921,390)	(1,967,217)
Net changes of items other than shareholders' equity	458,533	(269,725)
Total changes of items during the period	(2,450,857)	(2,224,943)
Balance at the end of current period	6,512,927	4,287,984

AnGes MG, Inc
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Year ended December 31, (From Jan. 1 to Dec.30)	
	2009	2010
Net cash (used in) operating activities		
Loss before income taxes	(2,910,202)	(1,947,057)
Depreciation and amortization	125,800	102,155
Interest income	(14,959)	(8,228)
Interest expenses	—	31
Foreign exchange losses	8,750	2,663
Loss on investments in partnership	334,052	82,939
Loss on retirement of noncurrent assets	25,807	17,678
Loss on valuation of investment securities	100,029	17,879
Stock issuance cost	272	70
Share-based compensation expenses	40,255	46,862
(Increase) decrease in notes and accounts receivable-trade	10,832	(13,817)
(Increase) decrease in inventories	72,279	(119,954)
Increase in notes and accounts payable-trade	41,897	48,945
(Increase) decrease in advance payments	35,181	(59,112)
Increase (decrease) in accounts payable-other	(3,700)	18,384
(Decrease) in advances received	(90,464)	(27,436)
(Increase) decrease in other current assets	5,959	(11,518)
Increase (decrease) in other current liabilities	(6,348)	8,014
Decrease in other noncurrent assets	921	—
Subtotal	<u>(2,223,635)</u>	<u>(1,841,499)</u>
Interest income received	14,495	14,296
Interest expenses paid	—	(31)
Income taxes paid	(15,954)	(15,650)
Net cash (used in) operating activities	<u>(2,225,095)</u>	<u>(1,842,885)</u>
Net cash provided by (used in) investing activities		
Payments into time deposits	(500,000)	—
Proceeds from withdrawal of time deposits	500,000	500,000
Purchase of short-term investment securities	(1,699,988)	(1,440,399)
Proceeds from redemption of securities	1,200,000	2,036,970
Purchase of property, plant and equipment	(11,504)	(23,837)
Proceeds from sales of property, plant and equipment	—	19
Purchase of intangible assets	(33,665)	(23,901)
Purchase of investment securities	—	(97,000)
Deividends from Investment Funds	15,178	—
Purchase of long-term prepaid expenses	(2,719)	—
Payments for lease and guarantee deposits	(700)	(401)
Proceeds from collection of lease and guarantee deposits	165	892
Other proceeds	2,719	—
Net cash provided by (used in) investing activities	<u>(530,513)</u>	<u>952,341</u>

AnGes MG, Inc
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Year ended December 31,	
	(From Jan. 1 to Dec.30)	
	2009	2010
Net cash (used in) financing activities		
Proceeds from issuance of common stock	11,727	11,929
Net cash (used in) financing activities	11,727	11,929
Effect of exchange rate change on cash and cash equivalents	(6,591)	(18,149)
Net increase (decrease) in cash and cash equivalents	(2,750,472)	(896,763)
Cash and cash equivalents at beginning of period	5,799,571	3,049,098
Cash and cash equivalents at end of period	3,049,098	2,152,335

AnGes MG, Inc
Nonconsolidated Balance Sheets
(In thousands)
(Unaudited)

	December 31, 2009	December 31, 2010
Assets		
Current assets		
Cash and deposits	3,397,057	2,051,275
Accounts receivable-trade	63,389	77,301
Short-term investment securities	1,498,278	900,235
Merchandise	33,447	60,283
Raw materials	471,496	567,577
Work in process	1,798	—
Supplies	6,574	5,739
Advance payments-trade	247,132	315,169
Prepaid expenses	26,403	24,276
Short-term loans receivable to subsidiaries and affiliates	200,000	—
Advances paid	1,442	1,388
Other	31,182	40,581
Allowance for doubtful accounts	(200,000)	—
Total current assets	<u>5,778,202</u>	<u>4,043,830</u>
Noncurrent assets		
Property, plant and equipment		
Buildings	40,230	40,420
Accumulated depreciation	(28,300)	(30,451)
Buildings, net	<u>11,930</u>	<u>9,969</u>
Machinery and equipment	2,143	2,143
Accumulated depreciation	(2,088)	(2,106)
Machinery and equipment, net	<u>54</u>	<u>36</u>
Tools, furniture and fixtures	312,443	350,113
Accumulated depreciation	(278,841)	(297,390)
Tools, furniture and fixtures, net	<u>33,601</u>	<u>52,722</u>
Total property, plant and equipment	<u>45,586</u>	<u>62,728</u>
Intangible assets		
Patent right	172,031	132,359
Right of trademark	543	329
Software	15,767	5,978
Telephone subscription right	86	86
Total intangible assets	<u>188,429</u>	<u>138,753</u>
Investments and other assets		
Investment securities	829,443	521,739
Stocks of subsidiaries and affiliates	61,684	61,684
Long-term loans receivable from subsidiaries and affiliates	—	200,000
Long-term prepaid expenses	69,453	56,679
Lease and guarantee deposits	53,221	52,895
Allowance for doubtful accounts	—	(200,000)
Total investments and other assets	<u>1,013,803</u>	<u>692,999</u>
Total noncurrent assets	<u>1,247,819</u>	<u>894,481</u>
Total assets	<u><u>7,026,021</u></u>	<u><u>4,938,311</u></u>

AnGes MG, Inc
Nonconsolidated Balance Sheets
(In thousands)
(Unaudited)

	December 31, 2009	December 31, 2010
Liabilities		
Current liabilities		
Accounts payable–trade	48,924	108,241
Accounts payable–other	57,693	75,868
Accrued expenses	6,635	5,901
Income taxes payable	22,125	21,339
Advances received	513,901	455,147
Deposits received	7,341	8,461
Total current liabilities	<u>656,622</u>	<u>674,959</u>
Total liabilities	<u>656,622</u>	<u>674,959</u>
Net assets		
Shareholders' equity		
Capital stock	9,460,618	9,466,618
Capital surplus		
Legal capital surplus	<u>7,771,361</u>	<u>7,777,361</u>
Total capital surpluses	<u>7,771,361</u>	<u>7,777,361</u>
Retained earnings		
Other retained earnings		
Retained earnings brought forward	<u>(11,333,394)</u>	<u>(13,196,520)</u>
Total earned surpluses	<u>(11,333,394)</u>	<u>(13,196,520)</u>
Total shareholders' equity	<u>5,898,584</u>	<u>4,047,458</u>
Valuation and translation adjustments		
Valuation difference on available–for–sale securities	<u>370,141</u>	<u>68,357</u>
Total valuation and translation adjustments	<u>370,141</u>	<u>68,357</u>
Subscription rights to shares	<u>100,673</u>	<u>147,535</u>
Total net assets	<u>6,369,399</u>	<u>4,263,351</u>
Total liabilities and net assets	<u><u>7,026,021</u></u>	<u><u>4,938,311</u></u>

AnGes MG, Inc
Nonconsolidated Statements of Operations
(In thousands)
(Unaudited)

	Year ended December 31, (From Jan. 1 to Dec.31)	
	2009	2010
Business revenues		
Net sales of goods	142,085	180,986
Research and development revenues	290,394	103,425
Total business revenues	<u>432,479</u>	<u>284,412</u>
Business expenses		
Cost of sales	68,210	82,813
Research and development expenses	2,099,659	1,325,196
Selling, general and administrative expenses	754,679	760,610
Total business expenses	<u>2,922,549</u>	<u>2,168,620</u>
Operating loss	<u>(2,490,069)</u>	<u>(1,884,208)</u>
Non-operating income		
Interest income	14,566	6,939
Interest on securities	5,518	4,741
Foreign exchange gains	—	24,728
Subsidy income	44,617	89,342
Office work fee from subsidiaries and affiliates	7,080	7,080
Fiduciary obligation fee	6,031	3,317
Miscellaneous income	775	3,077
Total non-operating income	<u>78,589</u>	<u>139,226</u>
Non-operating expenses		
Stock issuance cost	272	70
Loss on investments in partnership	330,084	80,757
Foreign exchange losses	12,028	—
Miscellaneous loss	16	—
Total non-operating expenses	<u>342,401</u>	<u>80,827</u>
Ordinary loss	<u>(2,753,881)</u>	<u>(1,825,810)</u>
Extraordinary income		
Reversal of allowance for doubtful accounts	100,000	—
Total extraordinary income	<u>100,000</u>	<u>—</u>
Extraordinary loss		
Loss on retirement of noncurrent assets	10,303	16,134
Loss on valuation of investment securities	100,029	17,879
Total extraordinary losses	<u>110,333</u>	<u>34,014</u>
Loss before income taxes	<u>(2,764,215)</u>	<u>(1,859,824)</u>
Income taxes—current	5,810	3,301
Net loss	<u>(2,770,025)</u>	<u>(1,863,126)</u>

AnGes MG, Inc
Nonconsolidated Statements of Changes in Net Assets
(In thousands)
(Unaudited)

	Year ended December 31, (From Jan. 1 to Dec.31)	
	2009	2010
Shareholders' equity		
Capital stock		
Balance at the end of previous period	9,454,618	9,460,618
Changes of items during the period		
Issuance of new shares—exercise of subscription rights to shares	6,000	6,000
Total changes of items during the period	<u>6,000</u>	<u>6,000</u>
Balance at the end of current period	<u>9,460,618</u>	<u>9,466,618</u>
Capital surplus		
Balance at the end of previous period	7,765,361	7,771,361
Changes of items during the period		
Issuance of new shares—exercise of subscription rights to shares	6,000	6,000
Total changes of items during the period	<u>6,000</u>	<u>6,000</u>
Balance at the end of current period	<u>7,771,361</u>	<u>7,777,361</u>
Retained earnings		
Balance at the end of previous period	(8,563,369)	(11,333,394)
Changes of items during the period		
Net loss	(2,770,025)	(1,863,126)
Total changes of items during the period	<u>(2,770,025)</u>	<u>(1,863,126)</u>
Balance at the end of current period	<u>(11,333,394)</u>	<u>(13,196,520)</u>
Total shareholders' equity		
Balance at the end of previous period	8,656,609	5,898,584
Changes of items during the period		
Issuance of new shares—exercise of subscription rights to shares	12,000	12,000
Net loss	(2,770,025)	(1,863,126)
Total changes of items during the period	<u>(2,758,025)</u>	<u>(1,851,126)</u>
Balance at the end of current period	<u>5,898,584</u>	<u>4,047,458</u>
Valuation and translation adjustments		
Valuation difference on available-for-sale securities		
Balance at the end of previous period	(46,016)	370,141
Changes of items during the period		
Net changes of items other than shareholders' equity	416,158	(301,784)
Total changes of items during the period	<u>416,158</u>	<u>(301,784)</u>
Balance at the end of current period	<u>370,141</u>	<u>68,357</u>
Subscription rights to shares		
Balance at the end of previous period	60,418	100,673
Changes of items during the period		
Net changes of items other than shareholders' equity	40,255	46,862
Total changes of items during the period	<u>40,255</u>	<u>46,862</u>
Balance at the end of current period	<u>100,673</u>	<u>147,535</u>

AnGes MG, Inc
Consolidated Statements of Changes in Net Assets
(In thousands)
(Unaudited)

	Year ended December 31, (From Jan. 1 to Dec.31)	
	2009	2010
Total net assets		
Balance at the end of previous period	8,671,011	6,369,399
Changes of items during the period		
Issuance of new shares—exercise of subscription rights to shares	12,000	12,000
Net loss	(2,770,025)	(1,863,126)
Net changes of items other than shareholders' equity	456,413	(254,921)
Total changes of items during the period	<u>(2,301,611)</u>	<u>(2,106,048)</u>
Balance at the end of current period	<u>6,369,399</u>	<u>4,263,351</u>